1. k inact / K I Value Determination for Penicillin-Binding Proteins in Live Cells.
- Author
-
Shirley JD, Gillingham JR, Nauta KM, Diwakar S, and Carlson EE
- Subjects
- Kinetics, beta-Lactams pharmacology, Microbial Sensitivity Tests, Boron Compounds, Penicillins, Penicillin-Binding Proteins metabolism, Penicillin-Binding Proteins genetics, Penicillin-Binding Proteins antagonists & inhibitors, Streptococcus pneumoniae drug effects, Streptococcus pneumoniae metabolism, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry
- Abstract
Penicillin-binding proteins (PBPs) are an essential family of bacterial enzymes that are covalently inhibited by the β-lactam class of antibiotics. PBP inhibition disrupts peptidoglycan biosynthesis, which results in deficient growth and proliferation, and ultimately leads to lysis. IC
50 values are often employed as descriptors of enzyme inhibition and inhibitor selectivity, but can be misleading in the study of time-dependent, covalent inhibitors. Due to this disconnect, the second-order rate constant, kinact / KI , is a more appropriate metric of covalent-inhibitor potency. Despite being the gold standard measurement of potency, kinact / KI values are typically obtained from in vitro assays, which limits assay throughput if investigating an enzyme family with multiple homologues (such as the PBPs). Therefore, we developed a whole-cell kinact / KI assay to define inhibitor potency for the PBPs in Streptococcus pneumoniae using the fluorescent, activity-based probe, Bocillin-FL. Our results align with in vitro kinact / KI data and show a comparable relationship to previously established IC50 values. These results support the validity of our in vivo kinact / KI method as a means of obtaining β-lactam potency for a suite of PBPs to enable structure-activity relationship studies.- Published
- 2024
- Full Text
- View/download PDF